HC Wainwright Predicts Reduced Earnings for SOPHiA GENETICS

Key Points

• HC Wainwright lowered its FY2029 EPS forecast for SOPHiA GENETICS to $0.31 from $0.34, while maintaining a Buy rating and $14 price target. It projects FY2030 EPS of $0.72.
• SOPHiA GENETICS reported a quarterly loss of $0.26 per share, missing the $0.21 consensus estimate, although revenue of $23.31 million exceeded expectations. The company remains deeply unprofitable, with a negative net margin of 93.86%.
• The stock traded down 7.9% and opened at $6.30, while analyst sentiment remained mixed: the consensus rating is Hold with a $10 target price, based on three Buy, one Hold and one Sell rating.

SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) - Stock analysts at HC Wainwright decreased their FY2029 earnings per share (EPS) estimates for shares of SOPHiA GENETICS in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.31 for the year, down from their prior forecast of $0.34. HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for SOPHiA GENETICS's current full-year earnings is ($0.58) per share. HC Wainwright also issued estimates for SOPHiA GENETICS's FY2030 earnings at $0.72 EPS.

A number of other brokerages have also recently issued reports on SOPH. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research boosted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Zacks Research raised SOPHiA GENETICS to a "hold" rating in a research report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $10.00.

SOPHiA GENETICS Trading Down 7.9%

SOPHiA GENETICS stock opened at $6.30 on Thursday. SOPHiA GENETICS has a 1 year low of $2.96 and a 1 year high of $7.21. The firm's 50-day moving average is $5.54 and its 200-day moving average is $5.12. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The company has a market cap of $528.51 million, a P/E ratio of -5.48 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 153.15%.

Insiders Place Their Bets

In other SOPHiA GENETICS news, insider Zhenyu Xu sold 10,000 shares of the business's stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $6.92, for a total transaction of $69,200.00. Following the completion of the transaction, the insider owned 600,887 shares in the company, valued at approximately $4,158,138.04. The trade was a 1.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 5,000 shares of the firm's stock in a transaction on Monday, July 27th. The shares were sold at an average price of $5.66, for a total value of $28,300.00. Following the transaction, the insider directly owned 223,387 shares in the company, valued at $1,264,370.42. This trade represents a 2.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 256,092 shares of company stock worth $1,492,420 over the last 90 days. Insiders own 4.88% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SOPH. 1492 Capital Management LLC acquired a new position in shares of SOPHiA GENETICS during the 4th quarter valued at $973,000. Royce & Associates LP acquired a new position in SOPHiA GENETICS during the fourth quarter worth about $2,009,000. Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS during the first quarter worth about $2,157,000. Royal Bank of Canada raised its position in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock worth $96,000 after acquiring an additional 18,781 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in SOPHiA GENETICS in the 1st quarter valued at about $1,772,000. 31.59% of the stock is currently owned by institutional investors.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: SOPHiA GENETICS raised its fiscal 2026 revenue outlook to $94 million–$96 million, above the roughly $93.4 million analyst consensus. Management continues to target adjusted EBITDA breakeven by year-end, which could improve confidence in the company’s path toward profitability. 2026 revenue outlook article
• Positive Sentiment: The company entered a multi-year collaboration with AstraZeneca to develop, validate and commercialize two companion diagnostics for precision-oncology therapies. The agreement may expand SOPH’s customer base and create longer-term opportunities in oncology testing. AstraZeneca partnership article
• Positive Sentiment: HC Wainwright raised its price target from $12 to $14 and BTIG Research increased its target from $8 to $9; both firms maintained Buy ratings. These revisions suggest some analysts see substantial upside if SOPH delivers on its growth and profitability targets. Analyst price target updates
• Neutral Sentiment: Chairman Jurgi Camblong, CTO Abhimanyu Verma and insider Zhenyu Xu collectively sold 35,000 shares worth approximately $242,350. Because all three transactions were conducted under pre-arranged Rule 10b5-1 plans and represented relatively small reductions in ownership, the sales provide limited information about management’s current outlook.
• Negative Sentiment: SOPH reported a quarterly loss of $0.26 per share, worse than the $0.21 loss analysts expected. Although revenue of $23.31 million exceeded the $21.72 million consensus, the company remains deeply unprofitable, with a negative net margin and analysts projecting a full-year loss. The earnings miss likely contributed to selling pressure. Q2 2026 earnings call transcript

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source